These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19143855)

  • 1. A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
    Kyle C; Zachariah J; Kinch H; Ellis G; Andrews C; Adekunle F
    Int J Clin Pract; 2008 Nov; 62(11):1684-92. PubMed ID: 19143855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
    Daniels S; Gitton X; Zhou W; Stricker K; Barton S
    J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty.
    Chan VW; Clark AJ; Davis JC; Wolf RS; Kellstein D; Jayawardene S
    Acta Anaesthesiol Scand; 2005 Nov; 49(10):1491-500. PubMed ID: 16223396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Hawkey CJ; Ell C; Simon B; Albert J; Keuchel M; McAlindon M; Fortun P; Schumann S; Bolten W; Shonde A; Hugot JL; Yu V; Arulmani U; Krammer G; Rebuli R; Toth E
    Clin Gastroenterol Hepatol; 2008 May; 6(5):536-44. PubMed ID: 18242145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    Fleischmann R; Tannenbaum H; Patel NP; Notter M; Sallstig P; Reginster JY
    BMC Musculoskelet Disord; 2008 Mar; 9():32. PubMed ID: 18328090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
    Willburger RE; Mysler E; Derbot J; Jung T; Thurston H; Kreiss A; Litschig S; Krammer G; Tate GA
    Rheumatology (Oxford); 2007 Jul; 46(7):1126-32. PubMed ID: 17478464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.
    Bitner M; Kattenhorn J; Hatfield C; Gao J; Kellstein D
    Int J Clin Pract; 2004 Apr; 58(4):340-5. PubMed ID: 15161117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
    Fricke J; Davis N; Yu V; Krammer G
    J Pain; 2008 Jan; 9(1):20-7. PubMed ID: 17933588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
    Hawkey CJ; Weinstein WM; Smalley W; Gitton X; Sallstig P; Stricker K; Krammer G; Mellein B; Richard D; Matchaba P
    Gastroenterology; 2007 Jul; 133(1):57-64. PubMed ID: 17631131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lumiracoxib is effective in the treatment of episodic tension-type headache.
    Packman E; Packman B; Thurston H; Tseng L
    Headache; 2005 Oct; 45(9):1163-70. PubMed ID: 16178946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
    Schnitzer TJ; Dattani ID; Seriolo B; Schneider H; Moore A; Tseng L; Sallstig P; Rebuli R; Maxwell T
    Clin Rheumatol; 2011 Nov; 30(11):1433-46. PubMed ID: 21607551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
    Rordorf C; Kellett N; Mair S; Ford M; Milosavljev S; Branson J; Scott G
    Aliment Pharmacol Ther; 2003 Sep; 18(5):533-41. PubMed ID: 12950426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    MacDonald TM; Reginster JY; Littlejohn TW; Richard D; Lheritier K; Krammer G; Rebuli R
    J Hypertens; 2008 Aug; 26(8):1695-702. PubMed ID: 18622250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
    Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.